购物车
全部删除
您的购物车当前为空
别名 Sintilimab (anti-PD-1), IBI308
Sintilimab (IBI308) 是一种人源化的 IgG4 单克隆抗体,具有显著的抗肿瘤活性,通过与 PD-1 结合从而阻断 PD-1 与其配体 (PD-L1 和 PL-L2) 的相互作用,进而恢复内源性抗肿瘤 T 细胞反应。Sintilimab 联合其他化合物来治疗经典霍奇金淋巴瘤、非小细胞肺癌和食管癌。

为众多的药物研发团队赋能,
让新药发现更简单!
Sintilimab (IBI308) 是一种人源化的 IgG4 单克隆抗体,具有显著的抗肿瘤活性,通过与 PD-1 结合从而阻断 PD-1 与其配体 (PD-L1 和 PL-L2) 的相互作用,进而恢复内源性抗肿瘤 T 细胞反应。Sintilimab 联合其他化合物来治疗经典霍奇金淋巴瘤、非小细胞肺癌和食管癌。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 1,490 | 现货 | |
| 5 mg | ¥ 3,890 | 现货 | |
| 10 mg | ¥ 5,970 | 现货 | |
| 25 mg | ¥ 8,870 | 现货 | |
| 50 mg | ¥ 12,200 | 现货 | |
| 100 mg | ¥ 16,300 | 现货 |
Sintilimab 相关产品
| 产品描述 | Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).Sintilimab is used in combination with other compounds for the treatment of classical Hodgkin's lymphoma, non-cellular lung cancer and esophageal cancer. Sintilimab is used in combination with other compounds to treat classical Hodgkin's lymphoma, non-small cell lung cancer and esophageal cancer. |
| 别名 | Sintilimab (anti-PD-1), IBI308 |
| 反应种属 | Human |
| 验证活性 | Immobilized PD-1-his at 2 μg/mL (30 μL/well) can bind sintilimab with the EC50 of 6.827 ng/mL. |
| 应用 | ELISA FACS Functional assay |
| 抗体种类 | Monoclonal |
| 内毒素 | < 1.0 EU/mg |
| 偶联 | Unconjugated |
| Uniprot ID |
| 分子量 | 144.04 kDa |
| CAS No. | 2072873-06-2 |
| 存储 | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
评论内容